Evidence map›Paper›PMID 28878650›Full record

ArticleCase reports in oncology

Interstitial Lung Disease Following Single-Agent Nanoparticle Albumin-Bound Paclitaxel Treatment in Patients with Advanced Non-Small Cell Lung Cancer.

Yuki Nakatani, Aya Nakaya, Takayasu Kurata, Takashi Yokoi, Yuki Takeyasu, Maiko Niki, Kayoko Kibata, Naoko Satsutani, Makoto Ogata, Takayuki Miyara and 1 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Yuki NakataniFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Aya NakayaFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Takayasu KurataFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Takashi YokoiFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Yuki TakeyasuFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Maiko NikiFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Kayoko KibataFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Naoko SatsutaniFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Makoto OgataFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Takayuki MiyaraFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Shosaku NomuraFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Kansai Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interstitial lung disease (ILD) is a serious and potentially fatal adverse event in lung cancer therapy. Nanoparticle albumin-bound paclitaxel (nab-PTX) is a novel, solvent-free formulation of paclitaxel (PTX). Although the incidence of nab-PTX-induced ILD is not clear, it is generally considered that this formulation presents a similar risk of developing ILD as PTX. Here, we report 3 patients who developed severe ILD following treatment with nab-PTX. We draw attention to the risk of developing drug-induced ILD following nab-PTX treatment, and highlight that this novel formulation might therefore not be as safe as PTX with respect to the development of ILD.

Indexed as

Interstitial lung diseaseNanoparticle albumin-bound paclitaxelNon-small cell lung cancerSingle-agent treatment

Identifiers

PMID28878650
PMCPMC5582424
OpenAlexW2743653872

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.